Tessellate Bio, a preclinical stage biotech company with a focus on novel synthetic lethality approaches, has emerged from stealth with an initial €8m in seed funding from two European venture capital firms, BioGeneration Ventures and Forbion.
Emerging From Stealth Mode, Tesselate Bio Looks To Develop Next-Gen Synthetic Lethality Drugs
As investment and interest grows in synthetic lethality cancer treatments, Netherlands-headquartered Tesselate Bio hopes to expand horizons within the field by hitting the novel FANCM target and developing its own companion diagnostic.
